KAB86901
Colorimetric
Plasma, Serum
Quantitative
15.625-1,000 ng/ml
CV<20%
80-120%
2-8 ℃
The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.
ABX-EGF,E7.6.3, CAS: 339177-26-3
Identification of Ion Channel-Associated Prognostic Biomarkers for Lung Adenocarcinoma., PMID:40493900
Identifying Molecular Probes for Fluorescence-Guided Surgery in Neuroblastoma: A Systematic Review., PMID:40426729
Exploring Real-World Outcomes of First Line EGFR Inhibitor Use, Cetuximab Versus Panitumumab, in Patients with Left-Sided, RAS Wild-Type, Metastatic Colorectal Cancer., PMID:40413126
Evaluation of the usefulness of protocol-based magnesium supplementation for hypomagnesemia in patients with advanced or recurrent colorectal cancer treated with panitumumab., PMID:40366467
Molecular Characterization and Clinical Outcomes of Pancreatic Neuroendocrine Neoplasms Harboring PAK4-NAMPT Alterations., PMID:40330142
Epidermal growth factor receptor antibody and axial elongation in experimental myopia., PMID:40326259
Construction and evaluation of a novel Stx2a-based immunotoxin against epidermal growth factor receptor (EGFR)., PMID:40315796
Targeting the MAP kinase pathway in colorectal cancer: A journey in personalized medicine., PMID:40310309
KRAS G12C inhibitors as monotherapy or in combination for metastatic colorectal cancer: A proportion and comparative meta-analysis of efficacy and toxicity from phase I-II-III trials., PMID:40274247
Efficacy and safety of oxaliplatin-based chemotherapy as first-line treatment in elderly patients with metastatic colorectal cancer: a meta-analysis., PMID:40260292
Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer., PMID:40215429
[A Case of Long-Term Prognosis of Advanced Rectosigmoid Cancer with Multiple Metastases Treated with Multidisciplinary Therapy]., PMID:40189763
Black Pigmentation on the Tongue Induced by Long-Term Use of Tetracycline Antibiotics in a Colorectal Cancer Patient With Epidermal Growth Factor Receptor (EGFR) Inhibitor-Associated Skin Lesions: A Case Report and Literature Review., PMID:40130130
Colorectal Cancer: Risk Factors, Novel Approaches in Molecular Screening and Treatment., PMID:40123590
Efficacy and safety of KRAS -G12C inhibitors in colorectal cancer: a systematic review of clinical trials., PMID:40116975
Response to anti-EGFR therapy in chemo-refractory right-sided RAS wild-type metastatic colorectal cancer: a case report and literature review., PMID:40115908
Background Tissue with Native Target Expression Can Determine Presence of Nodal Metastasis in Head and Neck Squamous Cell Carcinoma Patients Infused with Targeted Fluorescent Tracers., PMID:40100567
Treatment of extended RAS/BRAF wild-type metastatic colorectal cancer with anti-EGFR antibody combinations., PMID:40097366
HER2-targeted therapy in colorectal cancer: a comprehensive review., PMID:40087250
The emerging role of Sotorasib plus Panitumumab combination therapy in colorectal cancer treatment., PMID:40080361
Identifying distinct prognostic and predictive contributions of tumor epithelium versus tumor microenvironment in colorectal cancer., PMID:40075322
Costs of Adverse Event Management Associated with First-Line Cetuximab or Panitumumab in Metastatic Colorectal Cancer Patients in Saudi Arabia., PMID:40061835
Molecular Markers of Occult Lymph Node Metastasis in Head and Neck Squamous Cell Carcinoma (HNSCC) Patients., PMID:40018925
Aphthous-Like Stomatitis in a Patient Receiving Panitumumab., PMID:40017685
The Pharmacologic Inhibition of KRAS Mutants as a Treatment for Cancer: Therapeutic Principles and Clinical Results., PMID:40009739
Real-World Evidence of Bevacizumab and Panitumumab Drug Resistance and Drug Ineffectiveness from EudraVigilance Database., PMID:40002260
[A Case of Colorectal Cancer with Multiple Unresectable Liver Metastases That Achieved R0 after Chemotherapy and Laparoscopic Two-Stage Hepatectomy]., PMID:39949006
Could Panitumumab with very low dose Capecitabine be an option as a maintenance regimen., PMID:39945465
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C., PMID:39938112
Results of the Phase I/II Study and Preliminary B-cell Gene Signature of Combined Inhibition of Glutamine Metabolism and EGFR in Colorectal Cancer., PMID:39927885
Using methods to extend inferences to specific target populations to improve the precision of subgroup analyses., PMID:39924128
Monitoring of occupational exposure to hazardous medicinal products in robotic compounding., PMID:39890433
Beyond chemotherapy: Exploring 5-FU resistance and stemness in colorectal cancer., PMID:39863147
An Exosome-Based Liquid Biopsy Predicts Depth of Response and Survival Outcomes to Cetuximab and Panitumumab in Metastatic Colorectal Cancer: The EXONERATE Study., PMID:39820673
Neo-adjuvant FOLFOX with and without panitumumab for patients with KRAS-wt locally advanced colon cancer: results following an extended biomarker panel on the FOxTROT trial embedded phase II population., PMID:39805350
Panitumumab plus 5-fluorouracil and folinic acid or 5-fluorouracil and folinic acid alone as maintenance therapy in RAS wild-type metastatic colorectal cancer (PanaMa, AIO KRK 0212): final efficacy analysis of a randomised, open-label, phase 2 trial., PMID:39802302
Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer., PMID:39799855
AGITG MONARCC: A Randomized Phase 2 Study of Panitumumab Monotherapy and Panitumumab Plus 5-Fluorouracil as First-Line Therapy for Older Patients With RAS and BRAF Wild Type Metastatic Colorectal Cancer. A Study by the Australasian Gastro-Intestinal Trials Group (AGITG)., PMID:39779412
Au@109Pd Core-Shell Nanoparticles Conjugated to Panitumumab for the Combined β--Auger Electron Therapy of Triple-Negative Breast Cancer., PMID:39769315
Development of KRAS Inhibitors and Their Role for Metastatic Colorectal Cancer., PMID:39752885
Limited Efficacy of Anti-EGFR Monoclonal Antibodies in Colorectal Cancer Patients with Rare RAS Variants: Analysis of the C-CAT Database., PMID:39727997
[Case of Minocycline-Induced Thrombocytopenia during Chemotherapy for Ascending Colon Cancer]., PMID:39721793
The efficacy of targeted therapy and/or immunotherapy with or without chemotherapy in patients with colorectal cancer: A network meta-analysis., PMID:39716565
Second-line systemic treatment for metastatic colorectal cancer: A systematic review and Bayesian network meta-analysis based on RCT., PMID:39715232
Circulating Hepcidin Levels Are an Independent Predictor of Survival in Microsatellite Stable Metastatic Colorectal Cancer Patient Candidates for Standard First-Line Treatment., PMID:39682164
Prognostic value of radiologic and pathological response in colorectal cancer liver metastases upon systemic induction treatment: subgroup analysis of the CAIRO5 trial., PMID:39667310
Intensified Total Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer: Long-term Results of a Prospective Phase II Study., PMID:39667262
Post-marketing safety of panitumumab: a real-world pharmacovigilance study., PMID:39651795
The Use of Fluorescent Markers to Detect and Delineate Head and Neck Cancer: A Scoping Review., PMID:39629534
Effective Management of Severe Epidermal Growth Factor Receptor Inhibitors-Induced Papulopustular Eruption With Low-Dose Isotretinoin and Corticosteroids., PMID:39624566
Order: order@antibodysystem.com
Mail: support@antibodysystem.com
For research use only. Not for human or drug use.
Find out more about placing an order here
